Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasm Metastasis 9Ovarian Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Obesity 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Carcinoma In Situ 2Breast Cancer Metastatic 2Arthralgia 2Triple Negative Breast Neoplasms 1Sexuality 1Sexual Dysfunctions, Psychological 1Recurrence 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Pain 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Metastatic Beast Cancer 1Locoregional Recurrence 1Hyperglycemia 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hormone Receptor Positive Malignant Neoplasm of Breast 1HR Positive HER2 Negative Advanced Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 2High-Energy Shock Waves 2perflutren 1exemestane 1abemaciclib 1X-Rays 1Tamoxifen 1Specimen Handling 1Letrozole 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anatomic Stage III Breast Cancer AJCC v8 × exemestane × Clear all
NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
60 enrolled
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡